Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Stevens

Showing results (1-10 of 84) with videos related to

Pageof 9
Sort By:
Canadian Review of Sociology = Revue Canadienne De Sociologie|August 30, 2022
Foreign workers in the West: The regulation of migrant "Unfreedom" in SaskatchewanAndrew Stevens
International Journal of Technology Assessment in Health Care|June 5, 2004
Health technology assessment in England and WalesAndrew Stevens, Ruairidh Milne
The American Journal of Case Reports|July 25, 2019
Management of Ornithine Carbamoyltransferase Deficiency with Underlying Hyperammonia Hyperinsulinemia SyndromeNeer Dhillon, Andrew Stevens
Neurosurgical Focus|September 2, 2008
Deep brain stimulation for medically refractory epilepsyThomas L Ellis, Andrew Stevens
BMJ (Clinical Research Ed.)|May 19, 2007
The value of administrative databasesMohammed A Mohammed, Andrew Stevens
Journal of Public Health Medicine|July 10, 2003
HTA responses and the classic HTA reportRuairidh Milne, Andrew Clegg, Andrew Stevens
The Lancet. Oncology|January 21, 2011
NICE guidance on trastuzumab for the treatment of HER2-positive metastatic gastric cancerJoanne Holden, Zoe Garrett, Andrew Stevens
Journal of Public Health Medicine|July 10, 2003
Health technology assessment: history and demandAndrew Stevens, Ruairidh Milne, Amanda Burls
The Lancet. Oncology|October 17, 2006
Appraisal of bevacizumab and cetuximab for treatment of metastatic colorectal cancer in the UKDavid Barnett, Andrew Stevens, Carole Longson
The Lancet. Oncology|March 10, 2012
NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinibScott Goulden, Frances Sutcliffe, Andrew Stevens
Pageof 9

Showing results (1-10 of 84) with videos related to

Sort By:
Pageof 9
Canadian Review of Sociology = Revue Canadienne De Sociologie|August 30, 2022
Foreign workers in the West: The regulation of migrant "Unfreedom" in SaskatchewanAndrew Stevens
International Journal of Technology Assessment in Health Care|June 5, 2004
Health technology assessment in England and WalesAndrew Stevens, Ruairidh Milne
The American Journal of Case Reports|July 25, 2019
Management of Ornithine Carbamoyltransferase Deficiency with Underlying Hyperammonia Hyperinsulinemia SyndromeNeer Dhillon, Andrew Stevens
Neurosurgical Focus|September 2, 2008
Deep brain stimulation for medically refractory epilepsyThomas L Ellis, Andrew Stevens
BMJ (Clinical Research Ed.)|May 19, 2007
The value of administrative databasesMohammed A Mohammed, Andrew Stevens
Journal of Public Health Medicine|July 10, 2003
HTA responses and the classic HTA reportRuairidh Milne, Andrew Clegg, Andrew Stevens
The Lancet. Oncology|January 21, 2011
NICE guidance on trastuzumab for the treatment of HER2-positive metastatic gastric cancerJoanne Holden, Zoe Garrett, Andrew Stevens
Journal of Public Health Medicine|July 10, 2003
Health technology assessment: history and demandAndrew Stevens, Ruairidh Milne, Amanda Burls
The Lancet. Oncology|October 17, 2006
Appraisal of bevacizumab and cetuximab for treatment of metastatic colorectal cancer in the UKDavid Barnett, Andrew Stevens, Carole Longson
The Lancet. Oncology|March 10, 2012
NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinibScott Goulden, Frances Sutcliffe, Andrew Stevens
Pageof 9